SOURCE: Proteonomix

Proteonomix

May 23, 2011 11:45 ET

Proteonomix, Inc. (PROT) Animal Studies Confirms Potential Use of UMK-121

Studies Suggests Ability to Mobilize Stromal Stem Cells Into the Circulatory System

MOUNTAINSIDE, NJ--(Marketwire - May 23, 2011) - PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company ("Proteonomix" or the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to announce the results of animal studies involving the Company's UMK-121 technology.

The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells ("SSCs") into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses.

Ian McNiece, Proteonomix, Inc.'s Chief Scientific Officer, commented, "We continue to move forward building upon our existing scientific foundation. These tests provide us the first pre-clinical evidence of the potential viability of the UMK-121 technology. Further studies are planned to evaluate this approach in a model of tissue injury." He continued, "We continue to focus on our goal of initiating human clinical trials to demonstrate the efficacy of our stem cell products in various applications of regenerative medicine. Our ongoing progress in manufacturing has enabled the company to expand its intellectual property portfolio and will help establish the company as a key emerging player in the dynamic stem cell field."

Michael Cohen, President of the Company, added, "We look forward to our initial human clinical trial of the UMK-121 technology in the near future and have a strong belief that the results of that trial will catapult Proteonomix into the forefront of the plethora of development stage companies with stem cell technologies. Our initial target will be End Stage Liver Disease ("ESLD") patients. According to Organ Donation and Transplantation ("NWHIC") over 60,000 Americans suffer from End Stage Liver Disease ("ESLD"). If successful, UMK-121 promises to revolutionize the current modality of treatment for these patients. Further, the Company is exploring partnership and joint venture opportunities in order to develop its portfolio of intellectual properties ("IP"), including but not limited to its Cosmeceutical, Diabetes and Cardiac IP."

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI, The Sperm Bank of New York and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com, http://www.proteoderm.com, http://www.otcqb.com and http://www.sec.gov.

Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact Information